MYMETICS CORP - Quarter Report: 2016 September (Form 10-Q)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

 

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2016

 

OR

 

 

FOR THE TRANSITION PERIOD FROM __________ TO _________

 

COMMISSION FILE NUMBER: 000-25132

 

MYMETICS CORPORATION

(Exact name of registrant as specified in its charter)

 

DELAWARE		25-1741849
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

 

c/o Mymetics S.A.

Biopole

Route de la Corniche, 4

1066 Epalinges (Switzerland)

 

(Address of principal executive offices)

 

REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: 011 41 21 653 4535

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒           No ☐

             

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes ☒          No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “accelerated filer,” “large accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

 

 

	Large Accelerated Filer ☐		Accelerated Filer ☐
	Non-Accelerated Filer ☐		Smaller Reporting Company ☒

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   

Yes ☐         No ☒

                                             

Indicate the number of shares outstanding of each of the registrant's classes of common stock, as of the latest practicable date:

 

Class		Outstanding at November 14, 2016
Common Stock, $0.01 par value		303,757,622

 

 

 

PART I.    FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

MYMETICS CORPORATION

CONSOLIDATED BALANCE SHEETS

 (UNAUDITED)

(In Thousands of Euros)

 

 

	September 30,	December 31,
	2016	2015
ASSETS
Current Assets
Cash	$1,104	$2,381
Receivable other	55	218
Prepaid expenses	69	66
Total current assets	1,228	2,665
Property and equipment, net of accumulated depreciation of E407 at September 30, 2016    and E374 at December 31, 2015	76	106
In-process research and development	2,266	2,266
Goodwill	6,671	6,671
	$10,241	$11,708
LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)
Current Liabilities
Accounts payable	$75	$416
Deferred revenue from grants	486	1,014
Convertible notes payable to related parties	45,033	43,170
Total liabilities	45,594	44,600
Shareholders' Equity (Deficit)
Common stock, U.S. $0.01 par value;850,000,000 shares authorized;issued 303,757,622     at September 30, 2016 and at December 31, 2015	2,530	2,530
Preferred stock, U.S. $0.01 par value; 5,000,000 shares authorized; none issued or     outstanding	--	--
Additional paid-in capital	34,378	34,315
Accumulated deficit	(72,947)	(70,427)
Accumulated other comprehensive income	686	690
	(35,353)	(32,892)
	$10,241	$11,708

 

 

 

The accompanying notes are an integral part of these financial statements.

 

 

 

MYMETICS CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

 (UNAUDITED)

(In Thousands of Euros, Except Per Share Data)

 

 

 

 

	For The Three Months Ended September 30,		For The Nine Months Ended September 30,
	2016	2015	2016	2015
Revenue
Research and Development services	$30	$448	$379	$1,610
Grants	149	246	528	774
	179	694	907	2,384
Expenses
Research and development	241	455	599	1,376
General and administrative	298	376	930	1,216
Bank fee	1	--	2	2
Depreciation	11	13	33	32
Directors' fees	5	5	15	15
Foreign exchange and other	(20)	(11)	(62)	107
	536	838	1,517	2,748
Loss from operations	(357)	(144)	(610)	(364)
Interest Expense	642	642	1,926	1,928
Loss before income tax (provision) benefit	(999)	(786)	(2,536)	(2,292)
Income tax (provision) benefit	(4)	(4)	16	(14)
Net Loss	(1,003)	(790)	(2,520)	(2,306)
Other comprehensive Loss
Foreign currency translation adjustment	--	11	(4)	33
Comprehensive Loss	$(1,003)	$(779)	$(2,524)	$(2,273)
Basic earnings per share	$(0.00)	$(0.00)	$(0.01)	$(0.01)
Diluted earnings per share	$(0.00)	$(0.00)	$(0.01)	$(0.01)

 

 

The accompanying notes are an integral part of these financial statements.

 

MYMETICS CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

(In Thousands of Euros)

 

 

	For The Nine Months Ended September 30,
	2016	2015
Cash Flow from Operating Activities
Net loss	$(2,520)	$(2,306)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities
Depreciation	33	32
Stock compensation expense – options	63	119
Changes in operating assets and liabilities
Receivables	163	69
Accounts payable	(341)	16
Deferred revenue from grants	(528)	1,003
Accrued interest on notes payable	1,863	2,084
Other	(3)	2
Net cash provided by (used in) operating activities	(1,270)	1,019
Cash Flows from Investing Activities
Purchase of property and equipment	(3)	(18)
Net cash used in investing activities	(3)	(18)
Effect of foreign exchange rate on cash	(4)	33
Net change in cash	(1,277)	1,034
Cash, beginning of period	2,381	1,614
Cash, end of period	$1,104	$2,648

 

  The accompanying notes are an integral part of these financial statements. 

 

MYMETICS CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2016

(UNAUDITED)

 

Note 1. The Company and Summary of Significant Accounting Policies

 

BASIS OF PRESENTATION

 

The amounts in the notes are shown in thousands of EURO rounded to the nearest thousand except for share and per share amounts.

 

The accompanying interim period consolidated financial statements of Mymetics Corporation (the "Company" or “Mymetics”) set forth herein have been prepared by the Company pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the "SEC"). Certain information and footnote disclosure normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to such SEC rules and regulations. The interim period consolidated financial statements should be read together with the audited financial statements and the accompanying notes included in the Company's latest annual report on Form 10-K for the fiscal year ended December 31, 2015.

 

The accompanying financial statements of the Company are unaudited. However, in the opinion of the Company, the unaudited consolidated financial statements contained herein contain all adjustments necessary to present a fair statement of the results of the interim periods presented. All adjustments made during the three-month period ending September 30, 2016 were of a normal and recurring nature.

 

    Mymetics Corporation (the "Company" or "Mymetics") was created for the purpose of engaging in vaccine research and development. Its main research efforts in the beginning have been concentrated in the prevention and treatment of HIV and malaria and has later expanded to other vaccines for infectious diseases since the acquisition of Bestewil Holding BV in April 2009. The Company has established a network which enables it to work with education centers, research centers, pharmaceutical laboratories and biotechnology companies. The Company has the following vaccines under development; (i) Herpes Simplex which is at the pre-clinical stage and currently on hold, (ii) intranasal influenza which has finished a clinical trial Phase I for which the Company is seeking partners (iii) Respiratory Syncytial Virus (RSV) which is at the pre-clinical stage, (iv) HIV-1 which has finished a Phase I and has finished a repeat non-human primate study with the Texas Biomedical Research Institute, (v) malaria, which has finished a Phase Ib and a malaria transmission blocking vaccine which is in pre-clinical study with PATH-MVI and LMIV and (vi) two vaccine candidates that are currently in a discovery phase, one for Chikungunya and one for Zika.

 

    As of September 30, 2016, the Company is in the pre-clinical testing of some of its vaccine candidates and a commercially viable product is not expected for several more years. However, the Company generated some revenue through the licensing of its RSV vaccine and from collaboration and grant agreements for R&D services. Management believes that the Company’s research and development activities will result in valuable intellectual property that can generate significant revenues in the future such as by licensing. Vaccines are one of the fastest growing markets in the pharmaceutical industry.

 

These consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has experienced significant losses since inception resulting in an accumulated deficit of E72,947 at September 30, 2016. Further, the Company’s current liabilities exceed its current assets by E44,366 as of September 30, 2016, and there is no assurance that cash will become available to pay current liabilities in the near term. Management is seeking additional financing but there can be no assurance that management will be successful in any of those efforts. These conditions raise substantial doubt about our ability to continue as a going concern.

  

PRINCIPLES OF CONSOLIDATION

 

The consolidated financial statements include the accounts of the Company and its subsidiaries. Significant intercompany accounts and transactions have been eliminated.

 

FOREIGN CURRENCY TRANSLATION

 

The Company translates non-Euro assets and liabilities of its subsidiaries at the rate of exchange at the balance sheet date. Revenues and expenses are translated at the average rate of exchange throughout the period. Unrealized gains or losses from these translations are reported as a separate component of comprehensive income. Transaction gains or losses are included in general and administrative expenses in the consolidated statements of operations. The translation adjustments do not recognize the effect of income tax because the Company expects to reinvest the amounts indefinitely in operations. The Company's reporting currency is the Euro because substantially all of the Company's activities are conducted in Europe.

 

 

CASH

 

Cash deposits are occasionally in excess of insured amounts.

 

REVENUE RECOGNITION

 

  Exclusive Licenses

  The deliverables under an exclusive license agreement generally include the exclusive license to the Company’s technology, and may also include deliverables related to research activities to be performed on behalf of the collaborative collaborator and the manufacture of preclinical or clinical materials for the collaborative collaborator.

  Generally, exclusive license agreements contain non-refundable terms for payments and, depending on the terms of the agreement, provide that the Company will (i) provide research services which are reimbursed at a contractually determined rate which includes margin for the Company, (ii) participate in a joint steering committee to monitor the progress of the research and development which will be reimbursed at a contractually determined rate which includes margin for the Company, (iii) earn payments upon the achievement of certain milestones and (iv) earn royalty payments at the time of commercialization until the later of expiration of the last to expire valid patent rights expire or 10 years after the first commercial sale. The Company may provide technical assistance and share any technology improvements with its collaborators during the term of the collaboration agreements. The Company does not directly control when any collaborator will request research or manufacturing services, achieve milestones or become liable for royalty payments. As a result, the Company cannot predict when it will recognize revenues in connection with any of the foregoing.

  The Company follows the provisions of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 605-25, "Revenue Recognition—Multiple-Element Arrangements," and ASC Topic 605-28, "Revenue Recognition—Milestone Method," in accounting for these agreements. In order to account for these agreements, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on if certain criteria are met, including whether the delivered element has stand-alone value to the collaborator. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. Factors considered in this determination include the research and manufacturing capabilities of the collaborator and the availability of technology research expertise in the general marketplace.

RSV Corporation

  In December 2013, the Company entered into an agreement with RSV Corporation. The agreement provided RSV Corporation with an exclusive license to the Company’s RSV technology in order to develop and commercialize respiratory syncytial virus virosome vaccines. The Company received a US$5 million upfront payment in connection with the execution of the agreement and the Company was entitled to receive milestone payments potentially totaling $77 million plus royalties on product sales, if any. The Company also was entitled to receive payments for research and development activities performed on behalf of RSV Corporation. RSV Corporation was responsible for the development, manufacturing, and marketing of any products resulting from this agreement.

  In accordance with ASC 605-25, the Company identified all of the deliverables at the inception of the agreement. The significant deliverables were determined to be the RSV technology license and the research and development services including participation on the Joint Collaboration and Steering Committee (JCSC). The Company has determined that the RSV technology license had standalone value from the research services. As a result, the research services were considered a separate unit of accounting. The estimated selling prices for these units of accounting were determined based on market conditions and entity-specific factors such as the terms of the collaborators’ previous collaborative agreements, recent preclinical and clinical testing results of therapeutic products that use the Company’s RSV technology, the Company’s pricing practices and pricing objectives, and the nature of the research services to be performed for RSV Corporation and market rates for similar services. The arrangement consideration was allocated to the deliverables based on the relative selling price method. The Company recognized license revenue when the exclusive license was delivered pursuant to the terms of the agreement which was upon execution of the agreement. The Company recognized research services revenue as the related services were delivered.

  On January 25, 2016 Mymetics received notice from RSV Corporation (RSVC) that it will no longer pursue the development of a vaccine technology for Respiratory Syncytial Virus (RSV) in order to focus on other infectious therapies. The LCA which was signed on December 27, 2013, between Bestewil Holding BV and RSVC has formally been terminated as of July 25, 2016.

Fixed price contracts and research and collaboration agreements

  When the performance under a fixed price contract can be reasonably estimated, revenue for such a contract is recognized under the proportional performance method and earned in proportion to the contract costs incurred in performance of the work as compared to total estimated contract costs. Costs incurred under fixed price contracts represent a reasonable measurement of proportional performance of the work. Direct costs incurred under collaborative research and development agreements are recorded as research and development expenses. If the performance under a fixed price contract cannot be reasonably estimated, the Company recognizes the revenue on a straight-line basis over the contract term.

 

TEXAS BIOMEDICAL RESEARCH INSTITUTE

  In September 2014, the Company entered into a material transfer agreement and fixed price contract with Texas Biomedical Research Institute. The agreement provides Texas Biomedical Research Institute the lead of a project which has been proposed to the Bill and Melinda Gates Foundation with the objective to confirm previous results obtained in non-human primates with these virosome based HIV vaccine candidates. The Company has tested these different formulations of virosome based HIV vaccine candidates in preclinical non-human primate studies and in Phase I clinical settings. The Company produced and transferred to Texas Biomedical Research Institute the original material using the Company’s background IP.

 

  On April 11, 2016, the Company announced that its innovative HIV vaccine candidate was shown to generate significant protection in groups of 12 female monkeys against repeated AIDS virus exposures during part of the preclinical study. The blinded study was led by Dr. Ruth Ruprecht, Scientist & Director of the Texas Biomed AIDS Research Program and was funded by the Bill & Melinda Gates Foundation. During the first part of the study the Mymetics’ two-component virosome-based HIV vaccine was able to show significant efficacy of 87% in delaying the time to persistent infection versus the control group after seven intravaginal virus challenges. The study aimed to mimic the exposure of women to semen from HIV-infected men, although the viral dose of each of these seven animal challenges represented about 70,000 times the average human HIV dose passed during sexual intercourse from an HIV-infected male to an uninfected female. During the second part of the study the animal viral challenge dose was increased by 50% starting from the 8th challenge onward, reaching more than 100,000 times the average amount of virus passed from an infected man to a female partner. At this virus dose, the vaccine did not show significant protection in the animals as the immune system was overloaded. The Company is continuing its collaboration with the Texas Biomedical Research Institute to analyze the serum and mucosal samples to better understand the mechanisms of action of the vaccine. The Company recognizes revenue under the proportional performance method.

 

PATH-MVI

  In November 2014, the Company signed an agreement with PATH Malaria Vaccine Initiative (MVI) and the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the National Institute of Allergy and Infectious Diseases (NIAID), where Mymetics has developed and produced virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate which are based on two antigens provided by LMIV. The vaccine formulations were then tested in animal models. PATH MVI funded all activities under this project, which started in January 2015 and ended in January 2016. The Company has recognized revenue under the proportional performance method.

 

  On April 5, 2016, the Company announced that the preclinical study funded by PATH-MVI and in collaboration with LMIV where Mymetics’ virosome based formulations for a malaria transmission-blocking vaccine candidate were tested and compared with other vaccine formulations, had been successful. The study showed that the virosome vaccine candidates, at the highest dose tested, generate high antibody titers against the required antigens and they were able to significantly reduce (97-100%) the transmission of the Plasmodium falciparum parasite. The Company is currently evaluating funding opportunities for the next steps of development.

 

HORIZON 2020-SERI

  In April 2015, the Company was selected to receive project grants with a total of E8.4 million. A total of E5.3 million is funded as part of Horizon 2020, the European Union research and innovation framework program and up to E3.1 million of funding will be provided by the Swiss State Secretariat for Education, Research and Innovation (SERI) for the Swiss based consortium partners. The grant funds the evaluation, development and manufacturing scale-up of thermo-stable and cold-chain independent nano-pharmaceutical virosome-based vaccine candidates. Of the total amount, E3.4 million is directly attributable to Mymetics activities, with the remaining balance going to the consortium partners. The project duration is 42 months and started on May 4, 2015. In May 2015, the Company received a pre-payment from the two granting organizations for a total value of E1.5 million. The pre-payment has been recorded as a current liability and revenue has been recognized as services are delivered.

 

RECEIVABLES

 

Receivables are stated at their outstanding principal balances. Management reviews the collectability of receivables on a periodic basis and determines the appropriate amount of any allowance. There was no allowance necessary at September 30, 2016 or December 31, 2015. The Company charges off receivables to the allowance when management determines that a receivable is not collectible. The Company may retain a security interest in the products sold.

 

 

PROPERTY AND EQUIPMENT

 

Property and equipment is recorded at cost and is depreciated over its estimated useful life on straight-line basis from the date placed in service. Estimated useful lives are usually taken as three years.

 

IN-PROCESS RESEARCH AND DEVELOPMENT

 

In-process research and development (referred to as IPR&D) represents the estimated fair value assigned to research and development projects acquired in a purchased business combination that have not been completed at the date of acquisition and which have no alternative future use. IPR&D assets acquired in a business combination are capitalized as indefinite-lived intangible assets. These assets remain indefinite-lived until the completion or abandonment of the associated research and development efforts. During the periods prior to completion or abandonment, those acquired indefinite-lived assets are not amortized but are tested for impairment annually, or more frequently, if events or changes in circumstances indicate that the asset might be impaired.

 

IMPAIRMENT OF LONG LIVED ASSETS

 

Long-lived assets, which include property and equipment, are assessed for impairment whenever events or changes in circumstances indicate the carrying amount of the asset may not be recoverable. The impairment testing involves comparing the carrying amount to the forecasted undiscounted future cash flows generated by that asset. In the event the carrying value of the assets exceeds the undiscounted future cash flows generated by that asset and the carrying value is not considered recoverable, impairment exists. An impairment loss is measured as the excess of the asset’s carrying value over its fair value, calculated using a discounted future cash flow method. An impairment loss would be recognized in net income in the period that the impairment occurs.

 

GOODWILL

 

  Goodwill, which represents the excess of purchase price over the fair value of net assets acquired, is carried at cost. Goodwill is not amortized; rather, it is subject to a periodic assessment for impairment by applying a fair value based test. Goodwill is assessed for impairment on an annual basis as of April 1 of each year, unless events or circumstances indicate impairment may have occurred before that time. The Company assesses qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. After assessing qualitative factors, the Company must determine if further testing was necessary. If further testing was necessary, the Company would have performed a two-step impairment test for goodwill. The first step requires the Company to determine the fair value of each reporting unit. To the extent a reporting unit’s carrying amount exceeds its fair value, an indication exists that the reporting unit’s goodwill may be impaired and the Company must perform a second more detailed impairment assessment. The second impairment assessment involves allocating the reporting unit’s fair value to all of its recognized and unrecognized assets and liabilities in order to determine the implied fair value of the reporting unit’s goodwill as of the assessment date. The implied fair value of the reporting unit’s goodwill is then compared to the carrying amount of goodwill to quantify an impairment charge as of the assessment date.

 

  The Company has conducted its impairment testing as of April 1, of 2016 and 2015 of its goodwill recognized in connection to the acquisition of Bestewil. In conclusion of this impairment testing, the carrying amount of the reporting unit was lower than the estimated fair value of the reporting unit. As the fair value of the reporting unit is higher than the carrying amount, Step 2 of the goodwill impairment test did not need to be completed. As of September 30, 2016, management believes there are no indications of impairment.

 

 

 

 

 

EARNINGS PER SHARE

 

  Basic earnings per share is computed by dividing net income or loss attributable to common shareholders by the weighted average number of common shares outstanding in the period. Diluted earnings per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities. For the quarter ended September 30, 2016 and 2015, options, and convertible debt were not included in the computation of diluted earnings per share because their effect would be anti-dilutive due to net losses incurred under the treasury stock method.

 

  For the three months ended September 30, 2016, the basic weighted average number of shares was 303,757,622. The total potential number of shares issuable of 577,568,516 at September 30, 2016 includes 548,334,168 potential issuable shares related to convertible loans, and 29,234,348 potential issuable shares related to outstanding stock options granted to employees.

 

  For the nine months ended September 30, 2016, the basic weighted average number of shares was 303,757,622. The total potential number of shares issuable of 577,580,317 at September 30, 2016 includes 548,334,168 potential issuable shares related to convertible loans, and 29,246,149 potential issuable shares related to outstanding stock options granted to employees.

 

  For the three months ended September 30, 2015, the basic weighted average number of shares was 303,757,622. The total potential number of shares issuable of 541,314,490 at September 30, 2015 includes 511,734,490 potential issuable shares related to convertible loans, and 29,580,000 potential issuable shares related to outstanding stock options granted to employees.

 

  For the nine months ended September 30, 2015, the basic weighted average number of shares was 303,757,622. The total potential number of shares issuable of 537,477,124 at September 30, 2015 includes 511,734,490 potential issuable shares related to convertible loans, and 25,742,634 potential issuable shares related to outstanding stock options granted to employees.

 

PREFERRED STOCK

 

The Company has authorized 5,000,000 shares of preferred stock that may be issued in several series with varying dividend, conversion and voting rights. No preferred shares are issued or outstanding at September 30, 2016 or December 31, 2015.

 

STOCK-BASED COMPENSATION

 

  Compensation cost for all share-based payments is based on the estimated grant-date fair value. The Company amortizes stock compensation cost ratably over the requisite service period.

 

The issuance of common shares for services is recorded at the quoted price of the shares on the date the shares are issued. No shares were issued to individuals as fee for services rendered in the nine months ended September 30, 2016. As part of the 2013 stock option plan, the Company awarded 8,850,000 stock options grants to individuals in the nine months ended September 30, 2015. No stock option grants were issued to individuals for the three months ended September 30, 2015.

 

Stock compensation expense amounted to E63 and E119 during the nine month periods ended September 30, 2016 and 2015, respectively, and E18 and E33 during the three month periods ended September 30, 2016 and 2015, respectively, which is included in the statements of operations within general and administrative expenses.

 

ESTIMATES

 

The preparation of financial statements in conformity with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

FAIR VALUE MEASUREMENTS

 

Fair value guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:

 

 

 

The Company generally has the following financial instruments: cash, receivables, accounts payable, and notes payable. The carrying value of cash, receivables and accounts payable, approximates their fair value based on the short-term nature of these financial instruments. Management believes that it is not practicable to estimate the fair value of the notes payable due to the unique nature of these instruments.

 

CONCENTRATIONS

 

  The Company derived 42% and 64% of revenue from its relationship with one collaborative partner during the nine month periods ended September 30, 2016 and September 30, 2015, respectively, and 17% and 57% of revenue from its relationship with one collaborative partner during the three month periods ended September 30, 2016 and September 30, 2015, respectively. Furthermore, that same collaborative partner accounted for 5% and 68% of the receivables balance at September 30, 2016 and December 31, 2015, respectively.

 

RELATED PARTY TRANSACTIONS

 

An individual employed by the law firm that acts as the Company's general counsel is a member of the Board of Directors. The Company incurred professional fees to the counsel's law firm totaling E15 and E51 for the period of three and nine months ending September 30, 2016 and E8 and E46 for three and nine months ending September 30, 2015, respectively.

 

NEW ACCOUNTING PRONOUNCEMENTS

 

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 (ASU 2014-09), to supersede nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for the fiscal and interim reporting periods beginning after December 15, 2017 using either of two methods:

 

 

 

  Management is currently evaluating the impact of the Company's pending adoption of ASU 2014-09 on its consolidated financial statements.

 

Note 2. Intangible Assets

 

Intangible assets consisted of in process research and development at September 30, 2016 and December 31, 2015.

 

Note 3. Debt Financing

 

Certain principal shareholders have granted the Company secured convertible notes (in accordance with the Uniform Commercial Code in the State of Delaware) and short term convertible notes, which have a total carrying value of E45,033 including interest due to date. Interest incurred on these notes since inception has been added to the principal amounts.

   

   The details of the convertible notes and loans are as follows at September 30, 2016:

 

						Fixed
					Conversion	Rate
Lender	1st-Issue	Principal	Duration	Interest	Price	EUR/USD
Price	Date	Amount	(Note)	Rate	(stated)	Conversion
Eardley Holding A.G. (1)	06/23/2006	$170	(2)	10% pa	$0.10	N/A
Anglo Irish Bank S.A.(3)	10/01/2007	$500	(2)	10% pa	$0.50	1.4090
Round Enterprises Ltd.	12/10/2007	$1,500	(2)	10% pa	$0.50	1.4429
Round Enterprises Ltd.	01/22/2008	$1,500	(2)	10% pa	$0.50	1.4629
Round Enterprises Ltd.	04/25/2008	$2,000	(2)	10% pa	$0.50	1.5889
Round Enterprises Ltd.	06/30/2008	$1,500	(2)	10% pa	$0.50	1.5380
Round Enterprises Ltd.	11/17/2008	$1,200	(2)	10% pa	$0.50	1.2650
Round Enterprises Ltd.	02/06/2009	$1,500	(2)	10% pa	$0.50	1.2940
Round Enterprises Ltd.	06/15/2009	$5,500	(2,4)	10% pa	$0.80	1.4045
Eardley Holding A.G.	06/15/2009	$100	(2,4)	10% pa	$0.80	1.4300
Von Meyenburg	08/03/2009	$200	(2)	10% pa	$0.80	1.4400
Round Enterprises Ltd.	10/13/2009	$2,000	(2)	5% pa	$0.25	1.4854
Round Enterprises Ltd.	12/18/2009	$2,200	(2)	5% pa	$0.25	1.4338
Round Enterprises Ltd.	08/04/2011	$1,070	(5,6)	10% pa	$0.034	N/A
Eardley Holding A.G.	08/04/2011	$268	(5,6)	10% pa	$0.034	N/A
Round Enterprises Ltd.	11/08/2011	$400	(6)	10% pa	$0.034	1.3787
Eardley Holding A.G.	11/08/2011	$100	(6)	10% pa	$0.034	1.3787
Round Enterprises Ltd.	02/10/2012	$1,000	(6)	10% pa	$0.034	1.3260
Eardley Holding A.G.	02/14/2012	$200	(6)	10% pa	$0.034	1.3260
Round Enterprises Ltd.	04/19/2012	$322	(6)	10% pa	$0.034	1.3100
Eardley Holding A.G.	04/19/2012	$80	(6)	10% pa	$0.034	1.3100
Round Enterprises Ltd.	05/04/2012	$480	(6)	10% pa	$0.034	1.3152
Eardley Holding A.G.	05/04/2012	$120	(6)	10% pa	$0.034	1.3152
Round Enterprises Ltd.	09/03/2012	$200	(6)	10% pa	$0.034	1.2576
Eardley Holding A.G.	09/03/2012	$50	(6)	10% pa	$0.034	1.2576
Round Enterprises Ltd.	11/04/2012	$500	(6)	10% pa	$0.034	1.2718
Eardley Holding A.G.	12/06/2012	$125	(6)	10% pa	$0.034	1.3070
Round Enterprises Ltd.	01/16/2013	$240	(6)	10% pa	$0.034	1.3318
Eardley Holding A.G.	01/16/2013	$60	(6)	10% pa	$0.034	1.3318
Round Enterprises Ltd.	03/25/2013	$400	(6)	10% pa	$0.037	1.2915
Eardley Holding A.G.	04/14/2013	$150	(6)	10% pa	$0.034	1.3056
Round Enterprises Ltd.	04/14/2013	$600	(6)	10% pa	$0.034	1.3056
Eardley Holding A.G.	05/15/2013	$170	(6)	10% pa	$0.037	1.2938
Round Enterprises Ltd.	05/15/2013	$680	(6)	10% pa	$0.037	1.2938
Eardley Holding A.G.	06/24/2013	$60	(6)	10% pa	$0.025	1.3340
Round Enterprises Ltd.	06/24/2013	$240	(6)	10% pa	$0.025	1.3340
Eardley Holding A.G.	08/05/2013	$80	(6)	10% pa	$0.018	1.3283
Round Enterprises Ltd.	08/05/2013	$320	(6)	10% pa	$0.018	1.3283
Total Short Term Principal Amounts		$27,785
Accrued Interest		$17,248
TOTAL LOANS AND NOTES		$45,033

 

(1) Private investment company of Dr. Thomas Staehelin, member of the Board of Directors and of the Audit Committee of the Company. Face value is stated in U.S. dollars at $190.

 

(2) This maturity date is automatically prolonged for periods of three months, unless called for repayment.

 

(3) Renamed Hyposwiss Private Bank Geneve S.A. and acting on behalf of Round Enterprises Ltd. which is a major shareholder.

 

(4) The loan is secured against 2/3rds of the IP assets of Bestewil Holding BV and against all property of the Company.

 

(5) The face values of the loans are stated in U.S. dollars at $1,200 and $300, respectively.

 

(6) This maturity date is automatically prolonged for periods of three months, unless called for repayment. The conversion price per share is determined by the lower of (i) reducing by 10% the price per share of the Company’s common stock paid by the investors in connection with an investment in the Company of not less than US$20,000, or (ii) at the stated conversion price using a fixed exchange rate which are noted in the table above.

 

 

 

 

GENERAL

 

The following discussion and analysis of the results of operations and financial condition of Mymetics for the periods ended September 30, 2016 and 2015 should be read in conjunction with the Company's audited consolidated financial statements for the year ended December 31, 2015 and related notes and the description of the Company's business and properties included elsewhere herein.

 

This report contains forward-looking statements that involve risks and uncertainties. The statements contained in this report are not purely historical, but are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These forward looking statements concern matters that involve risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. Words such as "may," "will," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue", "probably" or similar words are intended to identify forward looking statements, although not all forward looking statements contain these words.

 

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We are under no duty to update any of the forward-looking statements after the date hereof to conform such statements to actual results or to changes in our expectations.

 

Readers are urged to carefully review and consider the various disclosures made by us which attempt to advise interested parties of the factors which affect our business, including without limitation disclosures made under the captions "Management Discussion and Analysis of Financial Condition and Results of Operations," "Risk Factors," "Consolidated Financial Statements" and "Notes to Consolidated Financial Statements" included in our annual report on Form 10-K for the year ended December 31, 2015 and, to the extent included therein, our quarterly reports on Form 10-Q filed during fiscal year 2016.

 

THREE MONTHS ENDED SEPTEMBER 30, 2016 AND 2015

 

Revenue was E179 and E694 for the three months ended September 30, 2016 and 2015, respectively. E30 and E448 relate to the research and development services provided under a License and Collaboration Agreement for the RSV vaccine signed on December 23, 2013 for the respective periods ending September 30, 2016 and 2015. For the three months ended September 30, 2016 and 2015, additional revenue of E149 and E246, respectively, was received from the grant revenue recognized for the HIV and malaria projects.

 

Costs and expenses decreased to E536 for the three months ended September 30, 2016 from E838 (-36.0%) for the three months ended September 30, 2015.

 

Research and development expenses decreased to E241 in the current period from E455 (-47.0%) in the comparative period of 2015. This is mainly due to the decrease in RSV related laboratory cost due to the cancellation of the LCA signed on December 27, 2013 between Bestewil Holding BV and RSVC, which has formally been terminated as of July 25, 2016.

 

General and administrative expenses decreased to E298 in the three months ended September 30, 2016 from E376 (-20.7%) in the comparative period of 2015.

 

Interest expense was stable at E642 for the three months ended September 30, 2016 and for the three months ended September 30, 2015 related to existing loans from third party investors.

 

The Company reported a net loss of (E1,003), or (E0.00) per share, for the three months ended September 30, 2016, compared to a net loss of (E790), or (E0.00) per share, for the three months ended September 30, 2015.

 

NINE MONTHS ENDED SEPTEMBER 30, 2016 AND 2015

 

Revenue was E907 and E2,384 for the nine months ended September 30, 2016 and 2015, respectively, out of which, E379 was related to the research and development services provided under the LCA with RSVC and E528 was related to grant revenue recognized for the HIV and malaria projects, during the nine months ended September 30, 2016. For the nine month period ending September 30, 2015, E1,610 was related to the research and development services provided under a LCA with RSVC and E774 was related to the grant revenue recognized for the HIV and malaria projects.

 

 

Costs and expenses decreased to E1,517 for the nine months ended September 30, 2016 from E2,748 (-44.8%) for the nine months ended September 30, 2015, mainly due to a decrease in general and administrative costs, research and development costs and foreign exchange revaluation of mainly positions in USD.

 

Research and development expenses decreased to E599 in the current period from E1,376 (-56.5%) in the comparative period of 2015, mainly due to the decrease in RSVC laboratory cost due to the cancellation of the LCA signed on December 27, 2013 between Bestewil Holding BV and RSVC, which has formally been terminated as of July 25, 2016.

 

General and administrative expenses decreased to E930 in the nine months ended September 30, 2016 from E1,216 (-23.5%) in the comparative period of 2015 mainly due to bonus (E46) and professional services related to the European Grant preparation (E67) paid during the nine months ended September 30, 2015.

 

Interest expense decreased to E1,926 for the nine months ended September 30, 2016 from E1,928 for the nine months ended September 30, 2015 related to existing loans from third party investors.

 

The Company reported a net loss of (E2,520), or (E0.01) per share, for the nine months ended September 30, 2016, compared to a net loss of (E2,306), or (E0.01) per share, for the nine months ended September 30, 2015.

 

LIQUIDITY AND CAPITAL RESOURCES

 

We had cash of E1,104 at September 30, 2016 compared to E2,381 at December 31, 2015.

 

  Our first significant revenue has been generated through the exclusive negotiation fee recorded in September 9, 2013 and the license and collaboration agreement for our RSV vaccine signed on December 27, 2013. As consideration Mymetics had received an irrevocable and non-refundable upfront fee for the license of USD 5 million at the beginning of 2014 and we have received fixed monthly collaboration and R&D fees. Due to the ending of the License and Collaboration Agreement with RSVC, for 2016, we anticipate recognizing significantly less revenue related to the research and development activities related to the RSV vaccine and some revenue related to the Horizon 2020 project. New significant revenues will not be expected, unless and until a second major licensing agreement or other commercial arrangement is entered into with respect to our technology.

 

As of September 30, 2016, we had an accumulated deficit of approximately E73 million, and had net loss of E2,520 in the nine month period ending on that date. We expect to continue to incur net losses in the future for research, development and activities related to the future licensing of our technologies, and because of the accrual of interest payable on existing loans.

 

Net cash used in operating activities was E1,270 for the nine month period ended September 30, 2016 mainly due to the decrease in research and development revenue received from RSV Corporation.During the nine month period ending September 30, 2015 net cash provided in operating activities was E1,019.

 

Investing activities used cash of (E3) during the nine months ended September 30, 2016, compared to (E18) for the comparable period in 2015, all related to the purchase of equipment for our laboratory in Leiden.

 

Financing activities for the nine months ended September 30, 2016 and September 30, 2015 is NIL.

 

   Salaries and related payroll costs represent gross salaries for two executives, our CSO of Mymetics BV and nine employees. Under Executive Employment Agreements with our CEO and two CSOs, we pay our executive officers a combined amount of E65 per month.

 

   Our Swiss subsidiary, Mymetics S.A., has two employees on its payroll: Director of Finance and Head of Manufacturing and Quality. Mymetics BV has, in addition to the full time Chief Scientific Officer, three full-time assistants and one part-time assistant.

 

   We intend to continue to incur additional expenditures during the next nine months for additional research and development of our HIV and Malaria vaccines, which we will try to seek through collaborations with not-for-profit organizations. These expenditures will relate to the continued testing of its prototype vaccines and are included in the monthly cash outflow described above.

 

   In the past, we have financed our research and development activities primarily through debt and equity financings from various parties, while the last two years our financing was generated through a license and collaboration agreement and grant agreements.

 

   On June 19, 2015, through our wholly-owned Swiss subsidiary, Mymetics SA, we entered into an Agreement with Breslin AG ("Breslin"), under which Breslin agreed to serve as the exclusive advisor to advise and support Mymetics in finding an industry partner to assist with the further development of the intranasal flu vaccine program which had successfully completed a clinical Phase I trial. Solvay Pharmaceuticals, which was acquired by Abbott Laboratories in 2009, was a prior partner of Mymetics for the intranasal flu vaccine and had successfully completed a clinical Phase I trial with 100 patients but transferred the partnering rights back to Mymetics following a strategic refocusing by Abbott Laboratories. Under the terms of the Agreement, Mymetics has agreed to pay to Breslin a retainer of €7,500 per month for nine months, capped at €45,000, in addition to certain success fees for potential upfront and milestone payments and royalties based upon potential sales of Mymetics' intranasal flu vaccine product.

 

 

  We anticipate that our normal operations will require approximately E1,150 in the year ending December 31, 2016, which reflects in increased spending for the Horizon 2020 project . We will seek to raise the required capital from equity or debt financings, and grants through donors and potential partnerships with major international pharmaceutical and biotechnology firms. However, there can be no assurance that we will be able to raise additional capital on satisfactory terms, or at all, to finance our operations. In the event that we are not able to obtain such additional capital, we will be required to further restrict or even cease our operations.

 

Monthly fixed and recurring expenses for "Property leases" of E12 represent the monthly lease and maintenance payments to unaffiliated third parties for our offices, of which E4 is related to our executive office located at Route de la Corniche 4, 1066 Epalinges in Switzerland (100 square meters), and E8 related to Bestewil Holding B.V. and its subsidiary Mymetics B.V operating from a similar biotechnology campus near Leiden in the Netherlands, where they occupy 120 square meters.

 

Included in professional fees are legal fees paid to outside corporate counsel and audit and review fees paid to our independent accountants, and fees paid for investor relations.

 

Cumulative interest expense of E17,248 has been accrued on all of the Company’s outstanding notes and advances (see detailed table in Note 3 to the financial statements).

 

RECENT FINANCING ACTIVITIES

 

  During the nine month period ending September 30, 2016, our principal source of funds has been revenues related to a HIV/MACIVIVA project with Horizon 2020/SERI and a License and Collaboration Agreement (“LCA”) with RSV Corporation (“RSVC”) signed on December 27, 2013 to license Bestewil Holding BV.

 

We have filed or are in the process of filing several new grant applications with U.S. and European institutions in relation to our HIV and malaria vaccines.

 

  Management anticipates that our existing capital resources will be sufficient to fund our cash requirements through the next six months. We have enough cash presently on hand in conjunction with the collection of receivables, based upon our current levels of expenditures and anticipated needs during this period. For 2017, we will need additional funding through future collaborative arrangements, licensing arrangements, and debt and equity financings under Regulation D and Regulation S under the Securities Act of 1933. We do not know whether additional financing will be available on commercially acceptable terms when needed.

 

  If management cannot raise funds on acceptable terms when needed, we may not be able to successfully commercialize our technologies, take advantage of future opportunities, or respond to unanticipated requirements. If unable to secure such additional financing when needed, we will have to curtail or suspend all or a portion of our business activities and could be required to cease operations entirely. Further, if new equity securities are issued, our shareholders may experience severe dilution of their ownership percentage.

 

  The extent and timing of our future capital requirements will depend primarily upon the rate of our progress in the research and development of our technologies, our ability to enter into a partnership agreement with a major pharmaceutical company, and the results of our present and future clinical trials.

 

OFF-BALANCE SHEET ARRANGEMENTS

 

The Company does not have any off-balance sheet arrangements.

 

 

We are exposed to market risk from changes in interest rates which could affect our financial condition and results of operations. We have not entered into derivative contracts for our own account to hedge against such risk.

 

INTEREST RATE RISK

 

Fluctuations in interest rates may affect the fair value of financial instruments. An increase in market interest rates may increase interest payments and a decrease in market interest rates may decrease interest payments of such financial instruments. We have no debt obligations which are sensitive to interest rate fluctuations as all our notes payable have fixed interest rates, as specified on the individual loan notes.

 

 

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

 

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, as appropriate, to allow timely decisions regarding required disclosure. Our management, with the participation and supervision of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report and determined that our disclosure controls and procedures were effective.

 

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

 

No changes of internal control over financial reporting were made in the nine months ended September 30, 2016.

 

INHERENT LIMITATIONS ON EFFECTIVENESS OF CONTROLS

 

Our management, Ronald Kempers, who is now both CEO and CFO, does not expect that our disclosure controls or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the company have been detected.

 

These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

 

 

 

 

 

Neither we, nor our wholly owned subsidiaries Mymetics S.A., Bestewil Holding B.V. nor its subsidiary Mymetics B.V. are presently involved in any litigation incident to our business.

 

 

Not applicable.

 

 

None

 

 

None.

 

 

None.

 

 

None.

 

 

EXHIBIT NUMBER	DESCRIPTION
31.1	Rule 13a-14(a)/15d-14(a) Certification of Chief
31.2	Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer
32	Section 1350 Certification of Chief Executive Officer and Chief Financial Officer
101.INS	Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	MYMETICS CORPORATION
Dated:  November 14, 2016	By:	/s/ Ronald Kempers
		Chief Executive Officer / Chief Financial Officer

 

 

 

 18